Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2012 3
2014 2
2015 1
2016 3
2017 1
2018 2
2019 3
2020 4
2021 8
2022 15
2023 15
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

57 results

Results by year

Filters applied: . Clear all
Page 1
Dysgeusia in patients with advanced urothelial carcinoma receiving enfortumab vedotin, platinum-based chemotherapy, or immune check point inhibitors: time-course assessment using chemotherapy-induced taste alteration scale.
Miyake M, Nishimura N, Oda Y, Miyamoto T, Tomizawa M, Shimizu T, Hori S, Morizawa Y, Gotoh D, Nakai Y, Torimoto K, Fujii T, Tanaka N, Fujimoto K. Miyake M, et al. Among authors: oda y. J Chemother. 2024 Apr 17:1-13. doi: 10.1080/1120009X.2024.2340885. Online ahead of print. J Chemother. 2024. PMID: 38628149
Impact of Complete Surgical Resection of Metastatic Lesions in Patients with Advanced Renal Cell Carcinoma in the Era of Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors.
Shimizu T, Miyake M, Nishimura N, Yoshida T, Itami Y, Tachibana A, Omori C, Oda Y, Kohashi M, Tomizawa M, Onishi K, Hori S, Morizawa Y, Dotoh D, Nakai Y, Torimoto K, Tanaka N, Fujimoto K. Shimizu T, et al. Among authors: oda y. Cancers (Basel). 2024 Feb 19;16(4):841. doi: 10.3390/cancers16040841. Cancers (Basel). 2024. PMID: 38398232 Free PMC article.
Enfortumab vedotin following platinum-based chemotherapy and immune checkpoint inhibitors for advanced urothelial carcinoma: response, survival and safety analysis from a multicentre real-world Japanese cohort.
Miyake M, Nishimura N, Oda Y, Miyamoto T, Ohmori C, Takamatsu N, Itami Y, Tachibana A, Matsumoto Y, Kiba K, Tomioka A, Yamamoto H, Okajima E, Masaomi K, Sakamoto K, Tomizawa M, Shimizu T, Ohnishi K, Hori S, Morizawa Y, Gotoh D, Nakai Y, Torimoto K, Tanaka N, Fujimoto K; Nara Urological Research and Treatment Group. Miyake M, et al. Among authors: oda y. Jpn J Clin Oncol. 2024 Mar 9;54(3):329-338. doi: 10.1093/jjco/hyad170. Jpn J Clin Oncol. 2024. PMID: 38061911
Calibration experiments for radon in drinking water measurements using portable-type electrostatic-collection radon monitors.
Hosoda M, Omori Y, Hashimoto H, Matsumoto M, Yasuoka Y, Sanada T, Oda Y, Kiso M, Sampei A, Kranrod C, Tazoe H, Akata N, Taira Y, Tamakuma Y, Yamada R, Kudo H, Shimizu M, Tokonami S. Hosoda M, et al. Among authors: oda y. Radiat Prot Dosimetry. 2023 Nov 2;199(18):2203-2206. doi: 10.1093/rpd/ncad188. Radiat Prot Dosimetry. 2023. PMID: 37935002
Clinical impact of the intensity of follow-up cystoscopy in patients with high-risk non-muscle-invasive bladder cancer.
Miyake M, Nishimura N, Nishioka Y, Fujii T, Oda Y, Miyamoto T, Tomizawa M, Shimizu T, Owari T, Ohnishi K, Hori S, Morizawa Y, Gotoh D, Nakai Y, Torimoto K, Tanaka N, Imamura T, Fujimoto K. Miyake M, et al. Among authors: oda y. Int Urol Nephrol. 2024 Mar;56(3):827-837. doi: 10.1007/s11255-023-03851-3. Epub 2023 Nov 1. Int Urol Nephrol. 2024. PMID: 37910382
57 results